Kari D Roberts1, Roland Brown2, Andrea L Lampland3, Tina A Leone4, Kyle D Rudser2, Neil N Finer5, Wade D Rich6, T Allen Merritt7, Adam J Czynski7, Julie M Kessel8, Sajani M Tipnis9, Erin C Stepka10, Mark C Mammel3. 1. Department of Pediatrics, University of Minnesota, Minneapolis, MN. Electronic address: rober694@umn.edu. 2. Department of Biostatistics, University of Minnesota, Minneapolis, MN. 3. Department of Pediatrics, University of Minnesota, Minneapolis, MN; Department of Pediatrics, Children's Minnesota, St. Paul, MN. 4. Department of Pediatrics, Columbia University, New York, NY. 5. Department of Pediatrics, University of California-San Diego, San Diego, CA. 6. Department of Pediatrics, Sharp Mary Birch, San Diego, CA. 7. Department of Pediatrics, Loma Linda University, Loma Linda, CA. 8. Department of Pediatrics, University of Wisconsin-Madison, Madison, WI. 9. Department of Pediatrics, University of Mississippi, Jackson, MS. 10. Department of Pediatrics, University of Minnesota, Minneapolis, MN.
Abstract
OBJECTIVE: To determine if preterm infants with moderate respiratory distress syndrome on continuous positive airway pressure (CPAP) who received surfactant via a laryngeal mask airway (LMA) would have a decreased rate of intubation and mechanical ventilation compared with those on CPAP who did not receive surfactant. STUDY DESIGN: In this prospective, multicenter, randomized controlled trial, 103 premature infants 280/7-356/7 weeks gestation, ≥1250 g and ≤36 hours old on CPAP requiring fraction of inspired oxygen 0.30-0.40 were assigned to receive surfactant administered through an LMA then placed back on CPAP (LMA group) or maintained on CPAP with no surfactant administered (control group). The primary outcome was treatment failure necessitating intubation and mechanical ventilation in the first 7 days of life. RESULTS: Surfactant administration through an LMA (n = 50) significantly decreased the rate of intubation and mechanical ventilation compared with controls (n = 53): 38% vs 64%, respectively, OR 0.30 (95% CI 0.13, 0.70), P = .006, number needed to treat: 4). There were no serious adverse events associated with placement of the LMA or surfactant administration. CONCLUSIONS: In premature neonates with moderate respiratory distress syndrome, surfactant administered through an LMA decreased the rate of intubation and mechanical ventilation. This intervention may have significant impact on clinical care in both high and low resource settings. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01116921.
RCT Entities:
OBJECTIVE: To determine if preterm infants with moderate respiratory distress syndrome on continuous positive airway pressure (CPAP) who received surfactant via a laryngeal mask airway (LMA) would have a decreased rate of intubation and mechanical ventilation compared with those on CPAP who did not receive surfactant. STUDY DESIGN: In this prospective, multicenter, randomized controlled trial, 103 premature infants 280/7-356/7 weeks gestation, ≥1250 g and ≤36 hours old on CPAP requiring fraction of inspired oxygen 0.30-0.40 were assigned to receive surfactant administered through an LMA then placed back on CPAP (LMA group) or maintained on CPAP with no surfactant administered (control group). The primary outcome was treatment failure necessitating intubation and mechanical ventilation in the first 7 days of life. RESULTS: Surfactant administration through an LMA (n = 50) significantly decreased the rate of intubation and mechanical ventilation compared with controls (n = 53): 38% vs 64%, respectively, OR 0.30 (95% CI 0.13, 0.70), P = .006, number needed to treat: 4). There were no serious adverse events associated with placement of the LMA or surfactant administration. CONCLUSIONS: In premature neonates with moderate respiratory distress syndrome, surfactant administered through an LMA decreased the rate of intubation and mechanical ventilation. This intervention may have significant impact on clinical care in both high and low resource settings. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01116921.
Authors: Bernard Thébaud; Kara N Goss; Matthew Laughon; Jeffrey A Whitsett; Steven H Abman; Robin H Steinhorn; Judy L Aschner; Peter G Davis; Sharon A McGrath-Morrow; Roger F Soll; Alan H Jobe Journal: Nat Rev Dis Primers Date: 2019-11-14 Impact factor: 52.329
Authors: Fernando R Moya; Jan Mazela; Paul M Shore; Steven G Simonson; Robert Segal; Phillip D Simmons; Timothy J Gregory; Carlos G Guardia; Judy R Varga; Neil N Finer Journal: BMC Pediatr Date: 2019-05-11 Impact factor: 2.125
Authors: Ömer Erdeve; Emel Okulu; Kari D Roberts; Scott O Guthrie; Prem Fort; H Gözde Kanmaz Kutman; Peter A Dargaville Journal: Turk Arch Pediatr Date: 2021-11